Natural Products as A Promising Therapy for SARS COV-2; An Overview
Noor S. Jaafar,*1 and Iman S Jaafar **

*Department of Pharmacognosy and Medicinal Plants, College of Pharmacy, University of Baghdad, Baghdad, Iraq
** Department of Pharmaceutics, College of Pharmacy, Mustansiryah University, Baghdad, Iraq

Abstract
Recently emerging pandemic SARS CoV-2 conquered our world since December 2019. Continuous efforts have been done to find out effective immunization and precise treatment strategies. A way from therapeutic options that were tried in SARS CoV-2, an increased attention is directed to predict natural products and mainly phytochemicals as collaborative measures for this crisis. In this review, most of the mentioned compounds specially flavonoids (biacalin, hesperidin, quercetin, luteolin, and phenolic (resveratrol, curcumin, and theaflavin) exert their effect through interfering with the action of one or more of these proteins (spike protein, papain-like protease, 3-chymotryptsin-like cysteine protease, and RNA-dependent RNA polymerase) that are involved in viral life cycle beside the anti-inflammatory effect of these compounds. The triterpenoids (celastrol, escin and glycyrrhizin) and the alkaloids (lycorine and cepharanthine) mediated their effect mainly through anti-inflammatory activity.

Glycyrrhetinic acid (glycyrrhizin metabolite) dawn regulates ACE-2, and reduces protease expression, thus reduce viral entry. This review may be representing an initial step in long path for designing the successful and effective treatment or vaccine for this pandemic.

Keywords: SARS CoV-2, Remedsiver, Antiviral, Phytochemical, Interleukin.

Introduction
One of the main pathogens that mainly goals the respiratory system in human is coronavirus (CoV), which is be allied to the Coronaviridae family. Under the electron microscope CoV signifies spike like projections on its outer surface granting it a crown-like appearance; therefore the designation coronavirus (1). CoVs are miniature in size as well as consist of a single stranded RNA. The CoV family subgroups include alpha (α), beta (β), gamma (γ) in addition to delta (δ) coronavirus (2).
Earlier outbreaks of CoV consist of Middle East respiratory syndrome (MERS)-CoV as well as the severe acute respiratory syndrome (SARS)-CoV which have been previously categorized as agents that form abundant public health hazard (3). Recently Coronavirus disease 2019 (COVID-19), a new developed respiratory disease resulted from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has turn out to be pandemic (4).

SARS-CoV-2 is contemplating a novel human infecting β CoV. Phylogenetic studies of the SARS-CoV-2 genome show that the virus is closely correlated (by 88% identity) to two bat-derived SARS like CoVs and genetically distinct from SARS-CoV (by around 79% similarity) as well as MERS-CoV (5). These studies point out that bats may aid as the virus natural host , signifying that mammals are the almost certainly link between SARS-CoV-2 and humans (6).

**Transition**

Numerous reports have proposed that human to human transmission is a possible route for SARS-CoV-2 infection dispersal (7). All age groups are prone to infection which is transmitted via large droplets generated by both symptomatic and asymptomatic people. The infection can be transmitted even before onset of symptoms during patient coughing and sneezing. Even on clinical recovery patients could be infectious provided that the symptoms last (8). It has been stated that the virus can endure from 2 hours to few days in the droplets on the surfaces or else ground and may infect individuals at a distance of about 1.8 meters radius (9). Infection is acquired either by inhalation of the droplets or touching the mouth, nose, as well as eyes after contact with contaminated objects or surfaces. Both stool and contaminated water may also contain virus. As a result consequent transmission through aerosolization and/or fecal - oral route is strongly hypothesized (10).

**Pathogenesis**

Afterwards human body entrance , SARS-CoV-2 primary enters the host cells prior to replication (11). The upper respiratory tract mucosal lining epithelium is the main site for viral replication. Additional multiplication occurs in lower respiratory tract and alimentary mucosa (12). Angiotensin converting enzyme 2 ( ACE2) which has been broadly expressed in heart , lung and kidney has been recognized as the functional receptor by which SARS-CoV-2 enters the body mucosa (13).

The binding of the virus spike (S) protein (separated to the S1 and S2 part) to ACE2 activate SARS-CoV-2 infection. The attachment of the virus to the target host cells surface is expedites via binding of S1 part of the virus S protein to the ACE2 cellular receptor of the host. Viral S protein priming then requires S protein cleavage of S1 from S2 (and at another S2’ site) by the host cell serine protease TMPRSS2. The fusion of the cell membranes of both virus and host is driven by the S2 subunit of the virus (14). Moreover, variance response through T helper cells (type 1 and type 2) activates cytokine storm and both respiratory dysfunction besides hypoxemia induced by SARS-CoV-2 can cause myocardial cells impairment (15). This progress is related to inflammatory cytokines elevation including IL2, IL7, IL10, GCSF, IP10, MCP1, MIP1A in addition to TNFα (16).

**Symptoms**

The clinical manifestations of SARS-CoV-2 varying from asymptomatic infection to acute respiratory distress syndrome (ARDS) and multiple organ impairment. The average incubation period assessed to be 5.2 days (17). Commonly observed symptoms include fever, sore throat, cough, myalgia or fatigue, dyspnoea, headache, diarrhea as well as conjunctivitis (16, 18). In some severe cases serious respiratory syndromes, pneumonia, kidney impairment and even death may occur. Severe clinical patterns are witnessed in individuals with coexisting health conditions like cardiovascular disease, diabetes, lung disease and cancer (15, 19). Adverse outcomes are also more common in aged as well as frail patients (20).

**Diagnosis**

The initial identification of SARS-CoV-2 patients is based on the clinical manifestation incidence related to early disease stage development. Different diagnostic methods are used as confirmatory test for patients with SARS-CoV-2. Real-time Polymerase Chain Reaction (RT-PCR) considered as a standard diagnostic test which is based on the recognition of the SARS-CoV-2 sequence (21). Since the virus RNA has been isolated from both upper as well as lower respiratory tract samples, the collection of nasopharyngeal besides oropharyngeal swabs is the main method for diagnosis (22). Detection of SARS-CoV-2 RNA in stool and blood specimens has also been proved by numerous studies (23, 24).

Distinctive range of laboratory anomalies can be considered as an additional nonspecific laboratory characteristics for patients with SARS-CoV-2 (15, 25). An elevated level of serum C-reactive protein, alanine aminotransferase, lactate dehydrogenase and aspartate aminotransferase can be observed. High percentage of patients showed reduced albumin level (26). Hematological abnormality include lymphopenia, mild thrombocytopenia, prothrombin time prolongation and elevated D-dimer values (25, 27, 28). Both D-dimer and lymphopenia to a minor degree seem like to have the main prognostic associations (28).

Besides to the previously designated methods, antigen-antibody reaction based kits offer rapid diagnostic technique. This test exploits immune reaction of combined human antibodies i.e., immunoglobulin M (IgM) in addition to IgG through spike proteins of SARS-CoV-2 from the blood sample of patient (29).
Additional specific and more sensitive diagnostic tool for SARS-CoV-2 is computerized topography or CT. Related features of CT images are shown in the majority of patients including ground glass opacity and bilateral patchy infiltrates. Conventional chest X ray is less sensitive tool comparing to CT. In a very limited cases, ultrasound has been used as a diagnostic tool.

**Treatment**

Presently, there are no definite drugs or vaccine for potential treatment of SARS-CoV-2 till now. Treatment strategies are basically symptomatic and supportive. Nevertheless, to manage this disease some perspectives have been used. The single choice available is the practice of broad-spectrum antiviral agents such as Nucleoside analogues as well as HIV-protease inhibitors that could weaken virus infection till availability of precise antiviral drug. In preclinical trials for both SARS-CoV and MERS-CoV infections, remdesivir as per a nucleotide analogue has been stated to be effective agent through acting on the coronaviruses polymerase. Remdesivir acts by impeding into the RNA chain of budding viral and then results in its premature termination.

The combination of lopinavir/ritonavir, a protease inhibitor demonstrated a potent efficacy against SARS-CoV-2. A reduction in the viral load in SARS-CoV-2 patients was also observed with this combination. Another antiviral agent which is suggested as probable therapy is nelfinavir, a selective HIV protease inhibitor that revealed strong SARS-CoV-2 inhibition.

Other therapeutic options suggested for treatment are arbidol (antiviral agent with a broad-spectrum activity), interferons (antiviral cytokines), monoclonal antibody, convalescent plasma (plasma acquired from individuals recovered from SARS-CoV-2) and intravenous immunoglobulin.

**Conceivable natural products against SARS-CoV-2**

**Resveratrol**

It is a polyphenolic compound 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-hep tadiene 3,5-dione] (figure 2), and the main curcuminoid obtained from turmeric (Curcuma longa). Various interesting biological activities have been displayed by curcumin, such as antimicrobial, antioxidant, anticancer, antiviral, and others.

Zahedipour et al (2020) mentioned a suitable justification based on modern and previous studies (curcumin impeding viral cell entry, inhibiting virus encapsulation and viral protease enzyme as well as modifying diverse cellular signaling pathways) that encourage the planning of modern studies and clinical trials using curcumin as a therapeutic agent for SARS-CoV-2.

Chen et al (2020) evaluate the effect of a combination of phytochemicals (vitamin C, curcumin, and glycyrrhizic acid abbreviated as VCG Plus) against the coronavirus utilizing systems biology. The study revealed that this combination can have an action on 88 hub targets that are closely coupled and linked with immune and inflammatory responses. VCG Plus can modulate or regulate the innate immune response by influence NOD-like and toll-like signaling pathways.
Toll-like signaling pathways to stimulate interferon generation, activation and balancing T-cells, and for regulating the inflammatory response by inhibiting certain signaling pathways (PI3K/AKT, NF-κB, and MAPK). The inhibition of inflammatory response, in turn, prohibit cytokine storm which is observed in certain SARS-CoV-2 (52). In addition to the proved antiviral effect of curcumin against other viruses.

Rosha et al (2020) postulated that this phytochemical probably beneficial in SARS-CoV 2 patients through various actions as; antithrombotic activity since an elevated number of thrombotic events occur in those patients, anti-cytokines and antifibrotic effects could assist in lung involvement. The main pathway for SARS-CoV-2 cell entry might be interposed by curcumin (53).

Figure 2. Chemical structure of curcumin (54)

Biacalin

Biacalin is (7-glucuronic acid, 5,6-dihydroxyflavone, or 7-O-glycoside of biacalein) (figure 3). It is the main bioactive compound from the root of Scutellaria baicalensis, also it is present in the Thymus vulgaris L. leaves (55, 56). Chu et al (2015) proved through in vitro and in vivo (in mice) the antiviral activity of biacalin against influenza virus A (H1N1) as a powerful inducer of interferon-gamma (IFN-γ) in major IFN-γ producing cells (57). Jelic D et al (2016) showed in two assays that biacalin (the glycoside) and biacalein (the aglycone) are significant inhibitors for Src tyrosine kinase, inhibition of this receptor is associated with the decreased generation of inflammatory cytokines, one of which IL-6 in LPS-stimulated THP-1 cells. The inhibitory effect (anti-inflammatory effect) of biacalein is more than that of biacalin. In MTS cytotoxicity assay in THP-1 cells both of these flavonoids demonstrated no cytotoxicity (56).

Haixia Su et al (2020) investigated the inhibitory effect of biacalin and biacalein vs SARS-CoV-2 3CLpro. (58). 3CLpro is a 3-chymotrypsin-like cysteine protease this enzyme rules replication of coronavirus and is crucial for its life cycle (59). The antiviral effect of these compounds was also evaluated against a clinical isolate of SARS-CoV-2 in Vero E6 cells. Biacalin and biacalein have a distinctive binding mode with SARS-CoV-2 3CLpro which was determined by X-ray protein crystallography. A core of substrate-binding pocket formed by the interaction of two catalytic residues, the first is decisive S1/S2 subsites and the second is an oxyanion loop. To this pocket, the biacalin is ensconced acting or behaving as a shield opposite the catalytic dyad to avoid the peptide substrate from getting near the active site. So Haixia Su et al. stated that biacalin because of its simple chemical structure, ubiquitous mode of action and powerful antiviral effect along with safety profile could be tried as antiviral agent (58).

Figure 3. Chemical structure of (A) biacalin and (B) biacalein (56)

Hesperidin

It is a flavonoid glycoside, its aglycone is hesperetin (figure 4). Hesperidin was initially isolated from the citrus peel (60) and it is present in large amounts in sweet oranges and lemons (61). Hesperidin is used in diosmin manufacturing (62, 63). Hesperidin has anti-inflammatory, antiviral, antioxidant, and other pharmacological activities (61).

Haggag et al (2020) visualized the probability of using hesperidin as a prophylactic and adjuvant curative candidate for SARS-CoV-2. Haggag declared this vision according to previously reported outcomes that confirm the effectiveness and safety of this phytochemical. Hesperidin bans SARS-CoV-2 ingress to the lung cell through the disruption of ACE2 and SARS-CoV-2 receptor binding domain interaction by targeting the binding interface of SARS-CoV-2 Spike and ACE2 human receptors. Hesperidin ameliorates the host cellular immunity, minify inflammatory mediators’ release. Simultaneous administration of a mixture of hesperidin and diosmin along with heparin is essential for protection against thromboembolism (62, 63).

Meneguzzo et al (2020) mentioned that hesperidin could be an effective antiviral agent against SARS CoV-2 and its further mutations. Hesperidin is outperforming the other natural molecules as well as antiviral drugs that were advised in SARS-CoV-2 clinical trials as the binding tendency of it for all the major viral and cellular targets is robust. Hesperidin can interrupt the viral infection at different stages starting from virus entrance to the steward human cell, to the viral genome transcription and replication. It was
suggested that hesperidin might be effective prophylaxis since it prohibits virus spreading to other cells, it has a high safety index, short life span in the human body, and at high doses, hesperidin showed no sign of cytotoxicity. Hesperitin also displayed a good binding affinity to one or more targets. Hesperidin also displayed a good binding affinity to one or more targets.

**Figure 4. Chemical structure of :**

A. hesperidin  
B. hesperitin  

**Quercetin**

Is flavonol aglycone; (3,3′,4′,5,7-pentahydroxy-flavone) (figure 5), found in various vegetables and fruits. Quercetin demonstrated numerous effects such as antioxidant, antiproliferative, antibacterial, antiviral, and others. Previous studies reported that quercetin could reduce mortality resulted from severe pandemic influenza A complications. In a previous study, quercetin was shown to inhibit SARS-CoV entry to host cell. Biancatelli et al (2020) pointed for the use of a combination of vitamin C and quercetin for prophylaxis and early management of SARA COV-2 respiratory tract infections. Quercetin affects various enzymes and targets that are involved in the virus life cycle as reverse transcriptase enzymes, SARS 3CL protease in SARS-COV. Hydroxyl groups in quercetin and its derivatives inhibit SARS 3CL protease through binding to Gln189 site on this enzyme. Because SARS COV-2 protease 3CL has the same binding site (Gln189) as SARS-COV so quercetin assumed to be effective for this pandemic. Vitamin C display immunomodulatory effect, boosting interferon formation, restrictive cytokine-mediated organ damage, enhance survival rate in lethal infection. Regarding this combination, a synergistic effect is gained, vitamin C is an antioxidant compound, has the ability for the generation of quercetin from oxidized quercetin derivatives. At the same time, both of these nutraceuticals exert antiviral and immunomodulatory effects.

Glinsky (2020) showed the feasibility of using putative combinations one composed of quercetin and vitamin D and the other quercetin, vitamin D, and estradiol for SARS-CoV-2. These combinations were more effective as treatment agents showed statistically more powerful effects on expression of SARS-CoV-2 target genes as compared to monotherapies. These agent separately or in combination alter the expression of genes encoding SARS-CoV-2 targets to varying degree which ultimately modulate the functions of viral proteins.

**Figure 5. Chemical structure of quercetin**

**Luteolin**

This flavone aglycone displayed antiviral effect (figure 6). Theoharides (2020) discussed the effective role of luteoline in SARS COV-2. Luteolin suppress viral entrance to host cell through binding to the SARS-CoV-2 spike S glycoprotein. Serine proteases, like SARS-CoV 3CL protease and other proteases were inhibited by luteolin. This flavone has anti-inflammatory effect. Tetramethoxyluteolin (luteolin derivative) decrease the secretion of the TNF and IL-1β (pro-inflammatory cytokines) from the mast cells. chemokines CCL2 and CCL were also inhibited.

**Figure 6. Chemical structure of luteolin**

**Theaflavin**

Theaflavin is a polyphenolic compound that has a benzotropolone skeleton (figure 7), it results from catechin oxidative condensation. This reddish-orange pigment (theaflavin) mainly founded in fermented tea, and anyhow very small quantities might be present in non-fermented tea (green tea). Chen et al (2005) in a study using fluorogenic substrate assay demonstrated that theaflavin-3,3′-digallate inhibit SARS-CoV 3CLpro more than theaflavin which might be explained by...
the absence of gallate group in theaflavin \(^\text{(75)}\). Lung et al \((2020)\) based on molecular docking studies demonstrated the probability of using theaflavin as a lead compound for evolving an inhibitor for SARS-CoV-2. According to the result of Lung's study theaflavin has the ability to docking in or targeting the catalytic pocket nearer the active site of RdRp (RNA-dependent RNA polymerase) in MERS-CoV, SARS-CoV, and SARS-CoV-2. RdRp is crucial for catalyzing the RNA replication from RNA templates. In the used molecular docking studies, theaflavin possess the lowest idock score and lower binding energy in the catalytic pocket of SARS-CoV-2 which may be explained by the fact that further hydrogen bonds along π-cation interaction were formed between theaflavin and the catalytic pocket of RdRp in SARS-CoV-2 \(^\text{(76)}\).

**Figure 7. Chemical structure of theaflavin \(^\text{(72)}\)**

**Glycyrrhizin**

Is a licorice bioactive compound that belongs to an acidic type of saponin glycosides (figure 8). This glycoside exhibits various clinical effects, one of which is the antiviral effect \(^\text{(77)}\). Luo P et al \((2020)\) perspective debates the possible use of glycyrrhizin as a SARS-COV-2 drug candidate based on its various pharmacological actions. The proposed mechanisms for using glycyrrhizin to conflict SARS-COV-2 may be via binding to ACE2, thus prevent the formation of SARS-COV-2 and ACE2 complex, inhibition of proinflammatory cytokines, thrombin, and cumulating IROS (intracellular reactive oxygen species). Airway exudates overproduction is inhibited while stimulating endogenous interferon \(^\text{(78)}\).

Harald Murck \((2020)\) discussed the protective effect of glycyrrhizin in SARS CoV-2 patients and its role in mitigating disease severity. His point of view was based on two main effects related to glycyrrhizin and its metabolite glycyrrhetinic acid (GA). GA firstly restrain an enzyme named 11-beta-hydroxysteroid dehydrogenase type 2, through the inhibition of this enzyme cortisol activate mineralocorticoid receptors which in turn dawn regulate ACE2 expression and thus reduce entry points of SARS CoV-2. Type 2 transmembrane serine protease serves as a cofactor for virus uptake by ACE2. GA reduces protease expression and offers a supplementary mechanism that limits virus entrance \(^\text{(79)}\). GA exerts anti-inflammatory effect through antagonism of Toll-like receptor 4, and thus decreases inflammation in many tissues including lungs. The production of inflammatory cytokines as TNFα, IL6, and IL18 are reduced.

As a result, GA neutralizes the mitigation of the ACE2 protective anti-inflammatory effect gained from reduced ACE2 expression due to GA used. ACE2 possesses an anti-inflammatory effect by the formation of angiotensin 1-7 and angiotensin 1-9 \(^\text{(79)}\).

**Figure 8. Chemical structure of A. glycyrrhizin and B. glycyrrhetinic acid \(^\text{(80)}\)**

**Escar**

Escar is a natural mixture of triterpenic saponins rather than a pure compound (figure 9), consisting of A, B, C and D escar, it is extracted from the horse chestnut seeds \(^\text{(81)}\). Previous studies reported the potent escar anti-inflammatory and anti-edematous actions \(^\text{(82)}\). Michelini et al \((2018)\) proved the antiviral effect of β-escar against HSV-1 infection \((\text{herpes simplex virus type 1})\). By the meaning of screening assay escar showed inhibitory effect vs SARS-CoV \(^\text{(83)}\).

Gallelli et al \((2020)\) demonstrated the possibility of using escar in combination with another antiviral agent as remdesivir as an effective therapeutic option for SARS CoV-2 patients suffering from acute lung injury. Gallelli and colleagues based in their outcome on the powerful anti-inflammatory effect of escar that is analogous to dexamethasone and methylprednisolone. In the late stage of SARS CoV-2 infection, the cytokine storm produces acute lung injury, escar might reduce the secretion of inflammatory mediators in addition to attenuate the acute lung injury. Several on ongoing clinical trials using escar oral and intravenous dosage form in SARA CoV-2 patients \(^\text{(84)}\).
Figure 9. Chemical structure of escin (81)

**Celastrol**

Is a pentacyclic triterpenoid of quinone methide type (figure 10), extracted from the root bark of *Tripterygium wilfordii*. It is used for the treatment of many conditions; tumors and rheumatoid arthritis in particular (85). Celastrol targets NFkB, anti-inflammatory, antioxidant mediators, and certain cell signaling molecules, exhibiting a potent anti-inflammatory effect (86). In a previous study celastrol along with other quinone methide triterpeniods proved as a potent inhibitor for SARS-CoV 3CLpro (87).

Law et al (2020) concluded that celastrol is an effective therapeutic option for SARS CoV-2 based on its powerful anti-inflammatory effect. Celastrol perhaps acts through inhibition of lipopolysaccharide and subsequent protein and mRNA expression that is encoding for pro-inflammatory cytokines like IL-6, IL8, and MCP-1 (Monocyte chemoattractant protein 1). The reduction in pro-inflammatory cytokines suppresses the phosphorylation step of the NF-kB, IKKa/β and IκBα. By suppression of this step, P56 is inactivated and the cascade of the inflammatory process is inhibited (88).

Figure 10. Chemical structure of celastrol (88)

**Lycorine**

Is a pyrrole[de]phenanthridine ring-type alkaloid (89) which was isolated from bulbs of *Narcissus pseudonarcissus* (90). Lycorine proved in a study to have an antiviral effect against SARS-CoV (Severe Acute Respiratory Syndrome associated coronavirus) (91). Shen et al (2020) showed the antiviral effect of 36 compounds against alpha and beta coronavirus that infect human among these virus HCoV-OC43 which cause encephalitis in mice. Lycorine demonstrated powerful antiviral action against multiple genetically distinct coronavirus in vitro and protected mice against lethal HCoV-OC43 infection in vivo (92).

Zank et al (2020) examined the antiviral effect of lycorine along with gemcitabine, and oxysophoridine vs SARS-CoV-2 in cell culture. These compounds demonstrated a dose-dependent antiviral effect that is not related to compound mediated cytotoxicity. Lycorine demonstrates various mechanisms as an antiviral agent for viruses other than SARS-CoV-2, but for the SARS-CoV-2 antiviral mechanism probably related to hosting factors modulation instead of targeting viral factors directly (93).

Figure 11. Chemical structure of lycorine (94)

**Cepharanthine**

This is benzylisoquinoline alkaloid (figure 11), isolated from *Stephania cephalantha*. it has anti-inflammatory, antioxidant properties used for the treatment of leukemia, alopecia, and other diseases (95).

Rogosnitzky et al (2020) et al (2020) in a review showed that cepharanthine might be a drug of choice and therapeutic option for SARS CoV-2. Cepharanthine interfered with certain enzymes and mediators generation that are involved in the viral entrance, replication, and in a cytokine storm. Among these deactivations of the nuclear factor-kappa B (NF-κB), cyclooxygenase expression, lipid peroxidation, nitric oxide, and cytokine formation (96).

Jeon et al (2020) evaluated the antiviral effect of 48 FDA- approved drugs as a candidate for SARS CoV-2 using chloroquine, lopinavir, and remdesivir as standards or reference drugs. Among the 48 tested drugs only 24 demonstrated the antiviral effect for SARS CoV-2, cepharanthine is included (97).
Other natural products

Narkhede et al. (2020) reported in a study using molecular docking studies the potential antiviral effect of several phytochemicals including berberine, tryptanthrine, indirubin, indican rhein, β-caryophyllene, β-sitosterol, these compound act via inhibition of viral protease (99).

Conclusion

Different phytochemicals and natural products were tried as possible treatment for SARS CoV-2. Alkaloids, phenolic, terpenes, and others were examples of these compounds. Flavonoids and phenolics were the compounds that are discussed in this review followed by triterpenes and lastly alkaloids. The pharmacological activities of these candidates were mediated through the direct effect on virus life cycle and/or via the anti-inflammatory effect which are beneficial in cytokine storm. Almost all the acquired data or information based on molecular docking studies (theoretical studies) and or previous studies related to MERS and SARS CoV. Further, in vitro and in vivo studies are required to find out the effective treatment for this pandemic.

Acknowledgment

Authors would like to express their deep appreciation to College of Pharmacy /University of Baghdad  www.uobaghdad.edu.iq/ and College of Pharmacy / University of Mustansiriyah (www.uomustansiriyah.edu.iq),Baghdad –Iraq for their support.

References

1. Richman DD, Whitley RJ, Hayden FG. Clinical virology: John Wiley & Sons; 2016.
2. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res 2020;24:91-8.
3. Bogoch II, Watts A, Thomas-Bachli A, Huber C, Kraemer MU, Khan K. Pneumonia of unknown aetiology in Wuhan, China: potential for international spread via commercial air travel. J Adv Res 2020;27(2):taaa008.
4. Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020;20(5):269-70.
5. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395(10224):565-74.
6. Huynh J, Li S, Yount B, Smith A, Sturges L, Olsen JC, et al. Evidence supporting a zoonotic origin of human coronavirus strain NL63. J Virol 2012;86(23):12816-25.
7. Wu P, Hao X, Lau EH, Wong JY, Leung KS, Wu JT, et al. Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020. Eurosurveillance. 2020,25(3):200044.
8. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med 2020;382(10):970-1.
9. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol 2020;94(7).
10. Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr 2020;87(4):281-6.
11. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020;367(6485):1444-8.
12. Gennaro F Di , Pizzol D, Marotta C, Antunes M, Rascalbuto V, Veronese N, Smith L. Coronavirus diseases (COVID-19) current status and future perspectives: A narrative review, Int. J. Environ. Res. Public Health 2020;17:2-11.
13. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama 2020;323(11):1061-9.
14. Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020;17(5):259-60.
15. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497-506.
16. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a
descriptive study. Lancet 2020 ;395 (10223) : 507-13.

17. Novel CPERE. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua liuxingbingxue zazhi 2020;41(2):145.

18. Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Resp Med 2020;8:475-481.

19. Ren L-L, Wang Y-M, Wu Z-Q, Xiang Z-C, Guo L, Xu T, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J 2020;133;1015-1040.

20. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis 2020;94:91-95.

21. Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses 2020;12(4):372.

22. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 2020;382(12):1177-9.

23. Zhang W, Du R-H, Li B, Zheng X-S, Yang X-L, Hu B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect 2020;9(1):386-9.

24. Zhang Y, Chen C, Zhu S, Shu C, Wang D, Song J, et al. Isolation of 2019-nCoV from a stool specimen of a laboratory-confirmed case of the coronavirus disease 2019 (COVID-19). China CDC Weekly. 2020;2(8):123-4.

25. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ov C-q, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382(18):1708-20.

26. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutierrez-Ocampo E, Villamizar-Pena R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis 2020;34:101623.

27. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-7.

28. Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA internal medicine 2020;180:1-11.

29. Liu W, Liu L, Kou G, Zheng Y, Ding Y, Ni W, et al. Evaluation of nucleocapsid and spike protein-based enzyme-linked immunosorbent assays for detecting antibodies against SARS-CoV-2. J Clin Microbiol 2020;58(6):1-7.

30. Kanne JP. Chest CT findings in 2019 novel coronavirus (2019-nCoV) infections from Wuhan, China: key points for the radiologist. Radiology 2020;295:16-17.

31. Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, et al. COVID-19 diagnosis and management: a comprehensive review. J Intern Med 2020;288:192-206.

32. Ali I, Alharbi OML. COVID-19: Disease, management, treatment, and social impact. Sci Total Environ 2020;728:138861.

33. Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio 2018;9(2):221-28.

34. Lim J, Jeon S, Shin H-Y, Kim MJ, Seong YM, Lee WJ, et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci 2020;35(6).

35. Yamamoto N, Yang R, Yoshinaka Y, Amari S, Nakano T, Cintal J, et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Biophys Res Commun 2004;318(3):719-25.

36. Khamitov R, Loginova S, Shchukina V, Borisevich S, Maksimov V, Shuster A. Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures. Vopr Virusol 2008;53(4):9-13.

37. Scagnolari C, Vicenzi E, Bellomi F, Stillitano MG, Pinna D, Poli G, et al. Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons. Antivir Ther 2004;9(6):1003-11.

38. Duan J, Yan X, Guo X, Cao W, Han W, Qi C, et al. A human SARS-CoV neutralizing antibody against epitope on S2 protein. Biochem Biophys Res Commun 2005;333(1):186-93.

39. Li H, Wang Y, Xu J, Cao B. Potential antiviral therapeutics for 2019 Novel Coronavirus. Zhonghua jiehe he huxi zazhi 2020;43:E002-E.

40. Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: from
mechanisms to potential therapeutic tools. Virol Sin 2020:1-6.
41. Silva P, Sureda A, Tur JA, Andreolletti P, Cherkaoui-Malki M, Latruffe N. How efficient is resveratrol as an antioxidant of the Mediterranean diet, towards alterations during the aging process? Free Radic Res 2019:55(sup1):1101-12.
42. Lin S-C, Ho C-T, Chao W-H, Li S, Wang TT, Lin C-C. Effective inhibition of MERS-CoV infection by resveratrol. BMC Infect Dis 2017;17(1):1-10.
43. Abba Y, Hassim H, Hamzah H, Noordin MM. Antiviral activity of resveratrol against human and animal viruses. Adv Virol 2015;2015:1-7.
44. Zhao X, Cui Q, Fu Q, Song X, Jia R, Yang Y, et al. Antiviral properties of resveratrol against pseudorabies virus are associated with the inhibition of IkB kinase activation. Sci Rep. 2017;7(1):1-11.
45. Marinella MA. Indomethacin and resveratrol as potential treatment adjuncts for SARS-CoV-2/COVID-19. Int J Clin Pract 2020:e13535.
46. Horne JR, Vohl M-C. Biological plausibility for interactions between dietary fat, resveratrol, ACE2, and SARS-CoV illness severity. Am J Physiol Endocrinol Metabol 2020;318(5):E830-E3.
47. Wahedia H M AS, Abbas S W. Stilbene-based natural compounds as promising drug candidates against COVID-19. J Biomol Struct Dyn 2020;1(10).
48. Hong YB, Kang HJ, Kim HJ, Rosen EM, Dakshanamurthy S, Rondanin R, et al. Inhibition of cell proliferation by a resveratrol analog in human pancreatic and breast cancer cells. Exp Mol Med 2009;41(3):151-60.
49. Perrone D, Ardito F, Giannatempo G, Dioguardi M, Troiano G, Lo Russo L, et al. Biological and therapeutic activities, and anticancer properties of curcumin. Exp Ther Med 2015;10(5):1615-23.
50. Patil S S BS, Rathod V K. Extraction of Curcuminoids From Curcuma Longa: Comparative Study Between Batch Extraction and Novel Three Phase Partitioning. Prep Biochem Biotechnol 2019;49(4):407-18.
51. Zahedipour F, Hosseini SA, Sathyapalan T, Majeed M, Jamialahmadi T, Al-Rasadi K, et al. Potential effects of curcumin in the treatment of COVID-19 infection. Phytother Res 2020;1-10.
52. Chen L, Hu C, Hood M, Zhang X, Zhang L, Kan J, et al. A Novel Combination of Vitamin C, Curcumin and Glycyrrhizic Acid Potentially Regulates Immune and Inflammatory Response Associated with Coronavirus Infections: A Perspective from System Biology Analysis. Nutrients 2020;12(4):1193.
53. Castro Rocha F A RdAM. Curcumin as a potential treatment for COVID-19. Phytother Res 2020:1-3.
54. Baskaran R, Madheswaran T, Sundaramoorthy P, Kim HM, Yoo BK. Entrapment of curcumin into monoolein-based liquid crystalline nanoparticle dispersion for enhancement of stability and anticancer activity. Int J Nanomedicine 2014;9:3119.
55. Liu R, Li X, Wei J, Liu S, Chang Y, Zhang J, et al. A single dose of baicalin has no clinically significant effect on the pharmacokinetics of cyclosporine A in healthy chinese volunteers. Front Pharmacol 2019;10:518.
56. Jeli D L-NDA. Brantner A H, BlaDekovi B, Bian B , Yang J , Brajša K, Vladimir-KneDevi S. Baicalin and Baicalein Inhibit Sre Tyrosine Kinase and Production of IL-6. J Chem 2016;2016:1-16.
57. Chu M, Xu L, Zhang M-b, Chu Z-y, Wang Y-d. Role of Baicalin in anti-influenza virus A as a potent inducer of IFN-gamma. Bio Med Res Int 2015;2015:1-11.
58. Su H, Yao S, Zhao W, Li M, Liu J, Shang W, et al. Discovery of baicalin and baicalein as novel, natural product inhibitors of SARS-CoV-2 3CL protease in vitro, bioRxiv 2020.
59. ul Qamar MT, Alqahtani SM, Alamri MA, Chen L-L. Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants. J Pharm Anal 2020:1-8.
60. Xiong H, Wang J, Ran Q, Lou G, Peng C, Gan Q, et al. Hesperidin: a therapeutic agent for obesity. Drug Des Devel Ther 2019;13:3855.
61. Hemanth Kumar B, Dinesh Kumar B, Diwan PV. Hesperidin, a citrus flavonoid, protects against L-methionine-induced hyperhomocysteinemia by abrogation of oxidative stress, endothelial dysfunction and neurotoxicity in Wistar rats. Pharm Biol 2017;55(1):146-55.
62. Tanaka T, Makita H, Kawabata K, Mori H, Kakumoto M, Satoh K, et al. Chemoprevention of azoxymethane-induced rat colon carcinogenesis by the naturally occurring flavonoids, diosmin and hesperidin. Carcinogenesis 1997;18(5):957-65.
63. Haggag YA, El-Ashtawy NE, Okasha KM. Is hesperidin essential for prophylaxis and treatment of COVID-19 Infection? Med Hypotheses 2020;144:1-3.
64. Meneguzzo F, Citrininna R, Zabini F, Pagliaro M. Review of Evidence Available on Hesperidin-Rich Products as Potential Tools against COVID-19 and Hydrodynamic Cavitation-Based Extraction as a Method of Increasing Their Production. Processes 2020;8(5):549.
65. Hamad M N, Jaafar NS, Abbas I S, Saleh Z. Comparison of the phenolic contents between...
65. Wu C, Li R, Li X, He J, Jiang S, Liu S, et al. Quercetin as an antiviral agent inhibits influenza A virus (IAV) entry. Viruses 2016;8(1):6

66. Yi L, Li Z, Yuan K, Qu X, Chen J, Wang G, et al. Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells. J Virol 2004;78(20):11334-9.

67. Colunga Biancatteli RML, Berrill M, Catravas JD, Markik PE. Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19). Front Immunol 2020;11:1451.

68. Glimsky GV. Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin D, Quercetin, and Estradiol Manifest Properties of Medicinal Agents for Targeted Mitigation of the COVID-19 Pandemic Defined by Genomics-Guided Tracing of SARS-CoV-2 Targets in Human Cells. Biomedicines 2020;8(5):1-26.

69. Theoharides TC. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin. Biofactors (Oxford, England). 2020;46:307-308.

70. Imran M, Rauf A, Abu-Izneid T, Nadeem M, Shariat MA, Khan IA, et al. Luteolin, a flavonoid, as an anticancer agent: A review. Biomed Pharmacother 2019;112:108612.

71. H EU. Chemistry of Tea. Comprehensive Natural Products II. 2010:999–1032.

72. Jiang Y, Hua J, Wang B, Yuan H, Ma H. Effects of variety, season, and region on theaflavins content of fermented Chinese Congou Black Tea. J Food Qual 2018;2018:1-9.

73. Ohba M, Oka T, Ando T, Arahata S, Ikegaya A, Ohba M, Oka T, Ando T, Arahata S, Ikegaya A, et al. The biological activity of alkaloids of variety, season, and region on theaflavins content of fermented Chinese Congou Black Tea. J Food Qual 2018;2018:1-9.

74. Chen C, Barrett B, Kwekkeboom K. Evid-Based Compl. Alt Med. 2016;2016:6295737.

75. Lung J, Lin YS, Yang YH, Chou YL, Shu LH, Cheng YC, et al. The potential chemical structure of anti-SARS-CoV-2 RNA-dependent RNA polymerase. J Med Virol 2020;92(6):693-7.

76. Noori WO, Waisi B, Alhassani MH. Extraction of glycyrrhizin from licorice (Glycyrrhiza Glabra L.) by bulk liquid membrane. Environ Technol Innov 2018;12:180-8.

77. LuoLiu P, Li J. Pharmacologic perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19. Int J Antimicrob Agents. 2020;55:1-4.

78. LuoLiu P, Li J. Pharmacologic perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19. Int J Antimicrob Agents. 2020;55:1-4.

79. Murck H. Symptomatic Protective Action of Glycyrrhizin (Licorice) in COVID-19 Infection? Front Immunol 2020;11:1-5.

80. Thakur A, Raj P. Pharmacological perspective of Glycyrrhiza glabra Linn: A mini-review. J Anal Pharm Res 2017;5:1-5.

81. Li M, Lu C, Zhang L, Zhang J, Du Y, Duan S, et al. Oral administration of escin inhibits acute inflammation and reduces intestinal mucosal injury in animal models. Evid Based Complement Alternat Med 2015;2015:1-9.

82. Huang Z-P, Liu X-J, Kou B-X, Wang L-G, Zhou T. The complete recanalization of PICC-related venous thrombosis in cancer patients: A series of case reports. Exp Ther Med 2013;6(2):411-2.

83. Michelin PM, Alché LE, Bueno CA. Virucidal, antiviral and immunomodulatory activities of β-escin and Aesculus hippocastanum extract. J Pharm Pharmacol 2018;70(11):1561-71.

84. Gallelli L, Zhang L, Wang T, Fu F. Severe Acute Lung Injury Related to COVID-19 Infection: A Review and the Possible Role for Escin. J Clin Pharmacol 2020;00:1-11.

85. Liu X, Zhao P, Wang X, Wang L, Zhu Y, Song Y, et al. Celastrol mediates autophagy and apoptosis via the ROS/JNK and Akt/mTOR signaling pathways in glioma cells. J Exp Clin Cancer Res 2019;38(1):1-18.

86. Venkatesha SH, Moudgil KD. Celastrol suppresses experimental autoimmune encephalomyelitis via MAPK/SGK1-regulated mediators of autoimmune pathology. Inflamm Res 2019;68(4):285-96.

87. Ryu YB, Park S-J, Kim YM, Lee J-Y, Seo WD, Chang JS, et al. SARS-CoV 3CLpro inhibitory effects of quinone-methide triterpenes from Tripterygium regelii. Bioorg Med Chem Lett 2010;20(6):1873-6.

88. Law S, Leung AW, Xu C. Is the traditional Chinese herb,” Celastrol” effective to combat COVID-19? J Mat Env Sci; 11:1205-1208.

89. Habartova K, Cahlíkova L, Řezáčová M, Havelek R. The biological activity of alkaloids from the Amaryllidaceae: from cholinesterases inhibition to anticancer activity. Nat Prod Commun 2016;11(10):1587-1594.

90. Shawky E, Hammoda H, Abou Donia A, Taima S, Kinoshita E, Takayama H. Phytochemical and Biological Investigation of Narcissus pseudonarcissus Cultivated in Egypt. RPBS 2018;2(1):26-34.

91. Li S-y, Chen C, Zhang H-q, Guo H-y, Wang H, Wang L, et al. Identification of natural compounds with antiviral activities against SARS-associated coronavirus. Antiviral Res 2005;67(1):18-23.

92. Shen L, Niu J, Wang C, Huang B, Wang W, Zhu N, et al. High-throughput screening and identification of potent broad-spectrum
inhibitors of coronaviruses. J Virol. 2019;93(12):1-15.
93. Zhang Y-N, Zhang Q-Y, Li X-D, Xiong J, Xiao S-Q, Wang Z, et al. Gemcitabine, lycorine and oxysophoridine inhibit novel coronavirus (SARS-CoV-2) in cell culture. Emerg Microbes Infect 2020;9:1-10.
94. Roy M, Liang L, Xiao X, Feng P, Ye M, Liu J. Lycorine: a prospective natural lead for anticancer drug discovery. Biomed Pharmacother 2018;107:615-24.
95. Bailly C. Cepharanthine: An update of its mode of action, pharmacological properties and medical applications. Phytomedicine 2019;62:1-12.
96. Rogosnitzky M, Okediji P, Koman I. Cepharanthine: A review of the antiviral potential of a Japanese-approved alopecia drug in COVID-19. Phytomedicine 2020;62:1-12.
97. Jeon S, Ko M, Lee J, Choi I, Byun SY, Park S, et al. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob Agents Chemother 2020;64:819-820.
98. Kikukawa Y, Okuno Y, Tatetsu H, Nakamura M, Harada N, Ueno S, et al. Induction of cell cycle arrest and apoptosis in myeloma cells by cepharanthine, a bisococlaurine alkaloid. Int J Oncol 2008;33(4):807-14.
99. Narkhede R R, Pise A V, Cheke R S, Shinde S D. Recognition of Natural Products as Potential Inhibitors of COVID 19 Main Protease (Mpro): In Silico Evidences, Nat Prod Bioprospect 2020;17:1-10.